Hikma Stands Firm On Supply As It Scoffs At Latest Amarin Lawsuit
Motion To Dismiss Filed; Advair Expectations Disclosed
Executive Summary
Hikma addressed supply concerns and the latest legal worries for its generic Vascepa product, as well as the recent launch of its long-awaited Advair generic, as management faced the virtual J.P. Morgan Healthcare Conference.
You may also be interested in...
Hikma Slams Amarin In Vascepa Antitrust Suit For ‘Locking Up API Supply’
Amarin is facing up to another antitrust lawsuit over its alleged control of API supply for its Vascepa brand.
Hikma’s Olafsson Offers Latest On Advair And Vascepa Rivals
Four key “moving pieces,” including the next developments for rivals to Advair and Vascepa, will influence the success of Hikma’s US generics business, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview.
What’s Next? Five Things To Look Out For In February
In the month ahead, Amarin is likely to reveal the latest on its plans to petition the US Supreme Court over generic versions of Vascepa, while biosimilar competition to Humira is set to arrive and the bulk of fourth-quarter and year-end financial results will emerge.